Recommended for Corporate Law, M&A, Private Equity, and Venture Capital.JUVE 2015/2016

Martin Neuhaus

Düsseldorf
  • Dreischeibenhaus 1
  • 40211 Düsseldorf
  • Germany
 
 

Dr. Martin Neuhaus is a corporate/M&A partner of Latham & Watkins in Germany and former Co-Chair of the German Corporate Department.

Mr. Neuhaus has extensive experience in domestic and cross-border M&A transactions, including public takeovers, private equity transactions, corporate restructurings, carve-outs, minority investments, and joint venture transactions.

He has advised multinational clients, such as Allianz, Axel Springer, Daimler, E.ON, IPIC/Aabar, Munich RE/ERGO, NOVA Chemicals, Novartis, RAG Stiftung, Scania, Syniverse, Tengelmann, and The Carlyle Group in some of their most significant transactions.

Mr. Neuhaus is listed as leading lawyer for M&A in Germany by IFLR1000 2017 and highly recommended for Corporate Law by clients (The Legal 500 Germany 2016). Additionally, he is recommended for M&A, Corporate Law, and Private Equity by JUVE 2016/2017.

He is a lecturer on cross-border M&A in the LLM program of the University of Münster. In addition, Mr. Neuhaus is a member of the German Corporate Law Association (VGR), the German-American Lawyer’s Association (DAJV),  and a graduate of Harvard Law School Executive Education.

Dr. Neuhaus’ experience includes, among others, advising:

  • Aabar Investments on its participation in Daimler, the establishment of an investment joint venture, ABAG, with Berndorf, Austria*
  • Allianz in the divestiture of a 40% stake in Beiersdorf, in the (indirect) divestiture of ASL and Disko Group, the acquisition of manroland, and the divestiture of juris*
  • Axel Springer in the acquisition and restructuring of PIN Group*
  • Capcellence regarding its private equity activities for HSH Nordbank*  
  • Daimler in connection with its participation in TollCollect
  • Deutsche Bank with respect to several EU cross-border mergers*
  • Droege Capital in the divestiture of Madaus Pharma to Rottapharm*  
  • E.ON on various transactions including the divestiture of its Hungarian gas storage and trading business and E.ON Kernkraft in view of the contemplated split-off from E.ON Group
  • IPIC on the acquisition of 70% in Ferrostaal, in compliance investigations on Ferrostaal and the subsequent unwinding of the Ferrostaal acquisition as well as on its participation in NOVA Chemicals*
  • Mayne Pharma (Hospira), amongst others, in each of the acquisitions of Onkoworks, Biologici, PHT Pharma*
  • NOVA Chemicals, amongst others, in the divestiture of its 50% stake in the global INEOS NOVA joint ventures to INEOS Group*
  • Novartis in the (failed) takeover of Aventis, acquisition of Hexal, the divestiture of Arevipharma, and regarding post-M&A disputes*
  • RAG Stiftung in the divestiture of a 25.01% stake in Evonik to CVC*
  • Scania on takeover and corporate law aspects*
  • SPP on the contemplated full ownership unbundling of eustream*
  • Tengelmann Group on the divestiture of its supermarket business Kaiser’s Tengelmann and its e-stores business to EDEKA
  • The Carlyle Group/Syniverse in the acquisition of global MACH Group and in the subsequent divestiture of MACH’s EEA data clearing and NRTRDE businesses*

*Matter handled prior to joining Latham

 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.